(Q38488577)

3 September 2017

1 reference

title

Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis (English)

1 reference

3 September 2017

1 reference

0 references

Erin Bauer

1

1 reference

3 September 2017

Jessica Lucier

series ordinal

2

1 reference

3 September 2017

Daniel E Furst

series ordinal

3

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 June 2015

1 reference

Expert Opinion on Biological Therapy

3 September 2017

1 reference

3 September 2017

15

1 reference

3 September 2017

6

1 reference

3 September 2017

883-893

1 reference

Psoriasis: epidemiology, clinical features, and quality of life

3 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Epidemiology of psoriatic arthritis in the population of the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Functional specialization of interleukin-17 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Signaling of interleukin-17 family cytokines in immunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

IL-17 cytokines in immunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

What have genome-wide studies told us about psoriatic arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

IL-17 receptor and its functional significance in psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Increased expression of interleukin 17 in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Role of interleukin-17F in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Regulation of inflammatory responses by IL-17F

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1045410

10.1517/14712598.2015.1045410

21 January 2018

Identifiers

DOI

1 reference

release_m3j4m2ha4zervccmxpc33e2dwq

3 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m3j4m2ha4zervccmxpc33e2dwq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference